B. Matija Peterlin, MD

Duke University, Durham, NC, B.S, 1968, Chemistry
Harvard Medical School, Boston, MA, M.D., 1973, Medicine

• 1973-1975
  Intern, Assistant Resident, Medicine, Stanford University Medical Center, Stanford, CA
• 1975-1977
  Research Associate, LMG, NICHD, NIH, Bethesda, Maryland Lt. Cmdr., USPHS
  Instructor, Georgetown University Medical School, Washington, DC
• 1977-1981
  Resident, Internal Medicine, Fellow, Rheumatology, Stanford University Medical Center, Stanford, CA
• 1981-1989
  Assistant Professor, Medicine, Microbiology and Immunology, University of California San Francisco, San Francisco, CA
• 1984-1990
  Associate Investigator, Howard Hughes Medical Institute, University of California San Francisco, San Francisco, CA
• 1989-1994
  Associate Professor, Medicine, Microbiology and Immunology, University of California San Francisco, San Francisco, CA
• 1991-1995
  Associate Investigator, Howard Hughes Medical Institute, University of California San Francisco, San Francisco, CA
• 1994-present
  Professor of Medicine, Medicine, Microbiology and Immunology, University California San Francisco, San Francisco, CA
• 1995-2001
  Investigator, Howard Hughes Medical Institute, University of California San Francisco, San Francisco, CA

• 1972-1973
  CoSTEP, USPHS, Harvard Medical School, Boston, MA
• 1978-1980
  Leukemia Society Fellow, Stanford U., Stanford, CA
• 1980-1981
  American Cancer Society Senior Fellow, Stanford U., Stanford, CA
• 1981-1982
  Rosalind Russell Scholar, UCSF, SF, CA
• 1995-present
  Alexander von Humboldt Prize, Bonn, Germany
• 1998-present
  Honorary Professor, U. Ljubljana, Slovenia

• Kao, S. Y., A. F. Calman, P. A. Luciw, and B. M. Peterlin. 1987. Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product. Nature 330:489-93.
• Tong-Starksen, S. E., P. A. Luciw, and B. M. Peterlin. 1987. Human immunodeficiency virus long terminal repeat responds to T-cell activation signals. Proc. Natl. Acad. Sci. USA 84:6845-9.
• Selby, M. J., E. S. Bain, P. A. Luciw, and B. M. Peterlin. 1989. Structure, sequence, and position of the stem-loop in TAR determine transcriptional elongation by Tat through the HIV-1 long terminal repeat. Genes Dev. 3:547-58.
• Tong-Starksen, S. E., P. A. Luciw, and B. M. Peterlin. 1989. Signaling through T lymphocyte surface proteins, TCR/CD3 and CD28, activates the HIV-1 long terminal repeat. J. Immunol. 142:702-7.
• Selby, M. J., and B. M. Peterlin. 1990. Trans-activation by HIV-1 Tat via a heterologous RNA binding protein. Cell 62:769-76.
• Tong-Starksen, S. E., and B. M. Peterlin. 1990. Mechanisms of retrovirus transcriptional activation. Sem. Virol. 1:215-227.
• Tong-Starksen, S. E., T. M. Welsh, and B. M. Peterlin. 1990. Differences in transcriptional enhancers of HIV-1 and HIV-2. Response to T cell activation signals. J. Immunol. 145:4348-54.
• Chin, D. J., M. J. Selby, and B. M. Peterlin. 1991. Human immunodeficiency virus type 1 Tat does not transactivate mature trans-acting responsive region RNA species in the nucleus or cytoplasm of primate cells. J. Virol. 65:1758-64.
• Alonso, A., D. Derse, and B. M. Peterlin. 1992. Human chromosome 12 is required for optimal interactions between Tat and TAR of human immunodeficiency virus type 1 in rodent cells. J. Virol. 66:4617-21.
• Carroll, R., B. M. Peterlin, and D. Derse. 1992. Inhibition of human immunodeficiency virus type 1 Tat activity by coexpression of heterologous trans activators. J. Virol. 66:2000-7.
• Ghosh, S., M. J. Selby, and B. M. Peterlin. 1993. Synergism between Tat and VP16 in trans-activation of HIV-1 LTR. J. Mol. Biol. 234:610-9.
• Luo, Y., S. J. Madore, T. G. Parslow, B. R. Cullen, and B. M. Peterlin. 1993. Functional analysis of interactions between Tat and the trans- activation response element of human immunodeficiency virus type 1 in cells. J. Virol. 67:5617-22.
• Luo, Y., and B. M. Peterlin. 1993. Juxtaposition between activation and basic domains of human immunodeficiency virus type 1 Tat is required for optimal interactions between Tat and TAR. J. Virol. 67:3441-5.
• Tong-Starksen, S. E., A. Baur, X. B. Lu, E. Peck, and B. M. Peterlin. 1993. Second exon of Tat of HIV-2 is required for optimal trans-activation of HIV-1 and HIV-2 LTRs. Virology 195:826-30.
• Adams, M., L. Sharmeen, J. Kimpton, J. M. Romeo, J. V. Garcia, B. M. Peterlin, M. Groudine, and M. Emerman. 1994. Cellular latency in human immunodeficiency virus-infected individuals with high CD4 levels can be detected by the presence of promoter- proximal transcripts. Proc. Natl. Acad. Sci. USA 91:3862-6.
• Alonso, A., T. P. Cujec, and B. M. Peterlin. 1994. Effects of human chromosome 12 on interactions between Tat and TAR of human immunodeficiency virus type 1. J. Virol. 68:6505-13.
• Jones, K. A., and B. M. Peterlin. 1994. Control of RNA initiation and elongation at the HIV-1 promoter. Annu. Rev. Biochem. 63:717-43.
• Luo, Y., H. Yu, and B. M. Peterlin. 1994. Cellular protein modulates effects of human immunodeficiency virus type 1 Rev. J. Virol. 68:3850-6.
• Mujeeb, A., K. Bishop, B. M. Peterlin, C. Turck, T. G. Parslow, and T. L. James. 1994. NMR structure of a biologically active peptide containing the RNA- binding domain of human immunodeficiency virus type 1 Tat. Proc. Natl. Acad. Sci. USA 91:8248-52.
• Wright, S., X. Lu, and B. M. Peterlin. 1994. Human immunodeficiency virus type 1 Tat directs transcription through attenuation sites within the mouse c-myc gene. J. Mol. Biol. 243:568-73.
• Ghosh, S., C. Toth, B. M. Peterlin, and E. Seto. 1996. Synergistic activation of transcription by the mutant and wild-type minimal transcriptional activation domain of VP16. J. Biol. Chem. 271:9911-8.
• Okamoto, H., C. T. Sheline, J. L. Corden, K. A. Jones, and B. M. Peterlin. 1996. Trans-activation by human immunodeficiency virus Tat protein requires the C-terminal domain of RNA polymerase II. Proc. Natl. Acad. Sci. USA 93:11575-9.
• Cujec, T. P., H. Cho, E. Maldonado, J. Meyer, D. Reinberg, and B. M. Peterlin. 1997. The human immunodeficiency virus transactivator Tat interacts with the RNA polymerase II holoenzyme. Mol. Cell. Biol. 17:1817-23.
• Cujec, T. P., H. Okamoto, K. Fujinaga, J. Meyer, H. Chamberlin, D. O. Morgan, and B. M. Peterlin. 1997. The HIV transactivator Tat binds to the CDK-activating kinase and activates the phosphorylation of the carboxy-terminal domain of RNA polymerase II. Genes Dev. 11:2645-57.
• Fujinaga, K., T. P. Cujec, J. Peng, J. Garriga, D. H. Price, X. Grana, and B. M. Peterlin. 1998. The ability of positive transcription elongation factor B to transactivate human immunodeficiency virus transcription depends on a functional kinase domain, cyclin T1, and Tat. J. Virol. 72:7154-9.
• Fujinaga, K., R. Taube, J. Wimmer, T. P. Cujec, and B. M. Peterlin. 1999. Interactions between human cyclin T, Tat, and the transactivation response element (TAR) are disrupted by a cysteine to tyrosine substitution found in mouse cyclin T. Proc. Natl. Acad. Sci. USA 96:1285-90.
• Taube, R., K. Fujinaga, J. Wimmer, M. Barboric, and B. M. Peterlin. 1999. Tat transactivation: a model for the regulation of eukaryotic transcriptional elongation. Virology 264:245-53.
• Wimmer, J., K. Fujinaga, R. Taube, T. P. Cujec, Y. Zhu, J. Peng, D. H. Price, and B. M. Peterlin. 1999. Interactions between Tat and TAR and human immunodeficiency virus replication are facilitated by human cyclin T1 but not cyclins T2a or T2b. Virology 255:182-9.
• Barboric, M., R. Taube, N. Nekrep, K. Fujinaga, and B. M. Peterlin. 2000. The binding of Tat to TAR and the recruitment of P-TEFb occur independently in BIV. J. Virol. 74:6039-44.
• Chao, S. H., K. Fujinaga, J. E. Marion, R. Taube, E. A. Sausville, A. M. Senderowicz, B. M. Peterlin, and D. H. Price. 2000. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication, J. Biol. Chem. 275:28345-28352.
• Kanazawa, S., T. Okamoto, and B. M. Peterlin. 2000. Tat competes with CIITA for the binding to P-TEFb and blocks the expression of MHC class II genes in HIV infection. Immunity 12:61-70.
• Okamoto, H., T. Cujec, M. Okamoto, B. M. Peterlin, M. Baba, and T. Okamoto. 2000. Fluoroquinoline derivatives, K-37, inhibits RNA-dependent transactivation by Tat of human immunodeficiency virus without affecting DNA-dependent transactivation. Virology 272:272-8.
• Okamoto, H., T. P. Cujec, B. M. Peterlin, and T. Okamoto. 2000. HIV-1 replication is inhibited by a pseudo-substrate peptide that blocks Tat transactivation. Virology. 270:337-44.
• Taube, R., K. Fujinaga, D. Irwin, J. Wimmer, M. Geyer, and B. M. Peterlin. 2000. Interactions between equine cyclin T1, Tat, and TAR are disrupted by a leucine-to-valine substitution found in human cyclin T1. J. Virol. 74:892-8.
• Kanazawa, S., and B.M. Peterlin, 2001. Repression of MHC determinants in HIV infection. Microbes Infect. 3:1-7.
• Barboric, M., R. Nissen, S. Kanazawa, N. Jabrane-Ferrat, and B.M. Peterlin 2001. NF-B Associates with P-TEFb to stimulate transcriptional elongation by RNA Polymerase II. Mol. Cell 8:327-337.
• Taube, R., X. Lin, D. Irwin, K. Fujinaga, and B.M.Peterlin. 2002. Interaction between P-TEFb and C-terminal domain of RNA polymerase II activates transcription from sites upstream and downstream of target genes. Mol. Cell. Biol. 22:321-331.
• Lind, K.E., Z. Du, K. Fujinaga, B.M. Peterlin, T.L. James. 2002. Structure-Based Computational Database Screening, In vitro Assay, and NMR Assessment of Compounds that Target TAR RNA. Chem Biol. 9: 185-193
• Lin, X., R. Taube, K. Fujinaga, and B.M. Peterlin. 2002. P-TEFb containing Cyclin K and Cdk9 activates transcription via RNA. J. Biol. Chem. 10:16873-16878.
• Fujinaga, K., J.D. Irwin and B.M. Peterlin. 2002. Optimized chimeras between kinase inactive, mutant Cdk9 and truncated cyclin T1 proteins inhibit efficiently Tat transactivation and HIV replication. J. Virol. 76:10873-10881
• Fujinaga, K., R. Taube, J.D. Irwin and B.M. Peterlin. 2002. A minimal chimera between human cyclin T1 and Tat binds TAR and activates HIV transcription in murine cells. J. Virol. 76:12934-12939.
• Jabrane-Ferrat, N., N. Nekrep., L. Esserman, and B.M. Peterlin. 2002. MHCII enhanceosome: How is CIITA recruited to DNA-bound activators? Internat. Immunol., In Press.
• Nekrep, N., N. Jabrane-Ferrat, H. Wolf, M. Eibl, M. Geyer and B.M. Peterlin. 2002. Point mutation in a winged-helix DNA-binding motif causes atypical bare lymphocyte syndrome. Nature Immunol. 3:1075-1081.
• Peterlin, B.M. and D. Trono. 2002. Hide, shield and strike back: How HIV-infected cells avoid immune eradication. Nat. Rev. Immunol. 3:97-107.
• Tosi, G. and B.M. Peterlin. 2002. Phosphorylation of CIITA directs its oligomerization, accumulation and increased activity on MHCII promoters. EMBO J. 21:5467-5476.
• Lin X., Yen, Y.S. Irwin, D., J. Romeo, L. Huang and B.M. Peterlin. 2003. Transcriptional profiles of latent HIV in infected individuals: Effects of Tat on the host and reservoir. J. Virol. 77:8227-8236.
• Nekrep, N., J.D. Fontes, M. Geyer and B.M. Peterlin. 2003. How the lymphocyte loses its clothes. Immunity 18:453-458.
• Peterlin, B.M. and D. Trono. 2003. Hide, shield and strike back: How HIV-infected cells avoid immune eradication. Nat. Rev. Immunol. 3:97-107.
• Uematsu, K., S. Kanazawa, L. You, B. He, Z. Xu, K. Li, B.M. Peterlin, F. McCormick and D.M. Jablons. 2003. Mesotheliomas have over expression of -catenin through activation of Dvl, and transcriptional activity of -catenin is correlated to tumorigenicity. Cancer Res. 63: 4547-4551.
• Zhang, F., M. Barboric, K.A. Blackwell, and B. M. Peterlin. 2003. A model for repression: CTD analogs and PIE-1 block transcriptional elongation by P-TEFb. Genes Dev. 17:748-758.
• Zheng, Y.H., and B.M. Peterlin. 2002. Human p32 protein relieves a post-transcriptional block to HIV replication in murine cells. Nat.Cell. Biol. 5:611-618
• Zheng, Y.H., A. Plemenitas, C.J. Fielding, and B.M. Peterlin. 2003. Nef increases the synthesis of and transports cholesterol to lipid rafts and HIV-1 progeny virions. Proc. Natl. Acad. Sci. USA 100:8460-8465.
• Costa, L.J., Y.H. Zheng, J. Sabotic, J. Mak, O.T. Fackler, B.M. Peterlin. 2004. Nef binds p6* in GagPol for optimal production and infectivity of HIV-1, J. Virol. 78:5311-5323.
• Kurosu, T., and B.M. Peterlin. 2004. VP16 and ubiquitin: Binding of P-TEFb via its activation domain and ubiquitin facilitates elongation of transcription of target genes, Curr. Biol., 14:1112-1116.
• Zheng, Y-H., D. Irwin, T. Kurosu, K. Tokunaga, T. Sata and B.M. Peterlin. 2004. Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J. Virol. 78:6073-6076.